Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nicole Northup"'
Autor:
Yves Pommier, James H. Doroshow, Jan H. Beumer, Julie Eiseman, Miguel Muzzio, Julianne L. Holleran, Joseph Tomaszewski, Heather Wilson-Robles, Nicole Northup, Kelvin Kow, Timothy Fan, Michael Kent, E.J. Ehrhart, Lisa Barber, Jeffrey N. Bryan, Michael Childress, David Vail, Erika Krick, William Kisseberth, Cheryl London, Kristen Weishaar, Sue Lana, Melissa Paoloni, Chand Khanna, Ralph E. Parchment, Robert J. Kinders, Jiuping Ji, Joseph M. Covey, Amy LeBlanc, Christina Mazcko, Jenna H. Burton
All supplementary files together
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6bc47299d9db5f59422b41191ade8c3
https://doi.org/10.1158/1078-0432.22469313
https://doi.org/10.1158/1078-0432.22469313
Autor:
Yves Pommier, James H. Doroshow, Jan H. Beumer, Julie Eiseman, Miguel Muzzio, Julianne L. Holleran, Joseph Tomaszewski, Heather Wilson-Robles, Nicole Northup, Kelvin Kow, Timothy Fan, Michael Kent, E.J. Ehrhart, Lisa Barber, Jeffrey N. Bryan, Michael Childress, David Vail, Erika Krick, William Kisseberth, Cheryl London, Kristen Weishaar, Sue Lana, Melissa Paoloni, Chand Khanna, Ralph E. Parchment, Robert J. Kinders, Jiuping Ji, Joseph M. Covey, Amy LeBlanc, Christina Mazcko, Jenna H. Burton
Purpose:Only one chemical class of topoisomerase I (TOP1) inhibitors is FDA approved, the camptothecins with irinotecan and topotecan widely used. Because of their limitations (chemical instability, drug efflux-mediated resistance, and diarrhea), nov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36108e2ffff164835c28b3a1445044dc
https://doi.org/10.1158/1078-0432.c.6527208
https://doi.org/10.1158/1078-0432.c.6527208
Autor:
Kristen M. Weishaar, Melissa Paoloni, Heather Wilson-Robles, Michael O. Childress, Christina Mazcko, Jenna H Burton, Yves Pommier, Michael S. Kent, Nicole Northup, Erika Krick, Joseph E. Tomaszewski, James H. Doroshow, Jiuping Ji, Timothy M. Fan, Cheryl A. London, Lisa G. Barber, William C. Kisseberth, David M. Vail, Robert J. Kinders, Jan H Beumer, Ralph E. Parchment, Chand Khanna, Miguel Muzzio, Amy K. LeBlanc, EJ Ehrhart, Julie Eiseman, Susan E. Lana, Joseph M. Covey, Julianne L. Holleran, Jeffrey N. Bryan, Kelvin Y Kow
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 23
Purpose: Only one chemical class of topoisomerase I (TOP1) inhibitors is FDA approved, the camptothecins with irinotecan and topotecan widely used. Because of their limitations (chemical instability, drug efflux-mediated resistance, and diarrhea), no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::195f890eef28379dc62ccbdeaccf96cb
https://escholarship.org/uc/item/2zt0643k
https://escholarship.org/uc/item/2zt0643k